Karyopharm Therapeutics Inc. KPTI
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-58.62
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $146.1M | -$196.0M | — | -$75.4M | -$292.9M |
| 2024 | $145.2M | -$76.4M | — | -$127.6M | -$186.0M |
| 2023 | $146.0M | -$143.1M | — | -$92.7M | -$136.2M |
| 2022 | $157.1M | -$165.3M | — | -$149.7M | -$16.7M |
| 2021 | $209.8M | -$124.1M | — | -$107.3M | -$79.7M |
| 2020 | $108.1M | -$196.3M | — | -$160.4M | $50.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Oliger Christy J. | director | 2026-05-21 | Grant | 15,508 | — |
| PAKIANATHAN DEEPIKA | director | 2026-05-21 | Grant | 15,508 | — |
| Schor Chen | director | 2026-05-21 | Grant | 15,508 | — |
| Su Zhen | director | 2026-05-21 | Grant | 15,508 | — |
| BOHLIN GAREN G | director | 2026-05-21 | Grant | 15,508 | — |
| Greene Barry E | director | 2026-05-21 | Grant | 15,508 | — |
| Abate Kristin | Chief Accounting Officer | 2026-05-14 | Sell | 53 | $9.50 |
| Poulton Stuart | EVP, Chief Development Officer | 2026-05-14 | Sell | 403 | $9.50 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -58.62 (distress)
- Working capital / assets 0.102
- Retained earnings / assets -16.229
- EBIT / assets -0.837
- Equity / liabilities -0.73
Source: SEC EDGAR filings · CIK 0001503802 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.